E N D O C A N N A B I N O I D S C I E N C E - - PowerPoint PPT Presentation

e n d o c a n n a b i n o i d s c i e n c e disclaimer
SMART_READER_LITE
LIVE PREVIEW

E N D O C A N N A B I N O I D S C I E N C E - - PowerPoint PPT Presentation

E N D O C A N N A B I N O I D S C I E N C E Disclaimer and cautionary note on forward-looking statements This presentation ("Presentation") contains information about Anandamida Gardens S.A.S. (the


slide-1
SLIDE 1

E N D O C A N N A B I N O I D S C I E N C E

slide-2
SLIDE 2

Disclaimer and cautionary note on forward-looking statements

This presentation ("Presentation") contains information about Anandamida Gardens S.A.S. (the "Company", "we", or "our"). Under no circumstances may the content of this Presentation be reproduced, in whole or in part, in any form or forwarded or redistributed to another person. Any forwarding, distribution or reproduction of this document in whole or in part is not authorized.By accepting and reviewing this document, you acknowledge

  • least a reasonable standard of care and not use any of the information contained in this document, except to assist you with your evaluation of the Company.

This presentation is for informational purposes only and does not constitute an offer to sell or a request for an offer to purchase Company securities. This presentation is not, and under no circumstances will it be interpreted as a prospectus, offering memorandum, advertisement or public offering of securities. The information in this document has been prepared in order to provide general information to interested parties to assist them in their evaluation of the Company. In this presentation, all dollar values are in American dollars, unless otherwise noted. Certain statements in this Presentation constitute "forward-looking statements" within the meaning of applicable Northamerican securities laws. Forward-looking statements are not historical facts or guarantees of future action. Instead, they are based on our current beliefs, expectations, assumptions, and analyzes made by us regarding the future of our business, future plans and strategies, our operating results, and other future

  • the forward-looking statements contained in this presentation on assumptions that we consider reasonable, these forward-looking statements involve risks, uncertainties, and other known and unknown factors that
  • and non-recurring items and other special items can be complex and necessarily depends on the particular facts of each of them.

Despite a careful process for preparing and reviewing forward-looking statements, the underlying opinions, estimates and assumptions cannot be guaranteed to be correct. The purpose of the forward-looking statements is to provide the reader with a description of management's expectations regarding our anticipated future performance and may not be appropriate for other purposes. Due to these risks, uncertainties and assumptions, the reader should not place undue reliance on these forward-looking statements. The Company's forward-looking statements are made only as of the date of this presentation, and except as required by

  • Market Research and Public Data - This presentation also contains or references certain market, industry, and peer group data that is based on information from independent industry publications, market research,
  • third-party sources referenced in this Submission, and therefore the accuracy and completeness of such data is not guaranteed.
  • applicable Colombian securities laws, such information is provided to demonstrate the Advance market penetration and the reader is cautioned that this information may not be appropriate for any other purpose and
  • additional information and are non-GAAP measures and do not have any standardized meaning prescribed by GAAP. They should not be considered in isolation as a substitute for performance measures prepared under

GAAP and are not necessarily indicative of operating costs presented under GAAP.

slide-3
SLIDE 3

About Us

“Clinical Cannabis has become a therapeutic compass to what modern medicine fails to cure”

  • Dr. Ethan Russo

Colombian company licensed for cannabis cultivation, research and manufacture of derivatives for medicinal purposes.

slide-4
SLIDE 4

What we have done

We have achieved brand recognition in Colombia and Latin America. Our cultivars are registered with the Colombian Agropecuary Institute (ICA) and we are getting ready for commercial production for local and export markets. We have developed cannabinoid formulas rich in terpenoids for the treatment of chronic diseases and we have a broad medical network in Colombia, which we support with continuing education programs.

Anandamide is a neurotransmitter that mimics the effects of compounds present in the cannabis plant, called cannabinoids. Its name derives from the Sanskrit word "ananda" which means inner bliss.

slide-5
SLIDE 5

Investment prospects

Global trend

1

2020 2021 2022 2023 2024 2025 2026 2027

North America

Source: Data Bridge Market Research 2020 *CAGR

20%

$30 $40 $50 $60 $70 $80 $90 $100 Billion $USD

Europe Asia South America Middle East and Africa

The global medical cannabis market is expected to account for $ 90.83 billion by 2027.

*CAGR: Compound annual growth rate

slide-6
SLIDE 6

Investment prospects

Solid legal framework

2

2016 2017 2018 2019 2020

Colombian Congress enacts Law 1787 that regulates access to medical and

  • Decree 613

regulates the production and transformation of medicinal cannabis Decree 1156 regulates the manufacturing, commercialization and sanitary registration for cannabis medications *INVIMA institute issues guide for processing of cannabis magistral preparations

The Colombian Government has developed a robust legislation that

  • research, and access to patients.

Decree 315 of 2020 regulates marketing

  • containing cannabis

*National Institute for Food and Drug Surveillance

slide-7
SLIDE 7

Investment prospects

Competitiveness

and geographical location

3

Low cost production, high standards

  • agricultural labor.

16 commercial agreements that support international trade from Colombia. Optimal cultivation variables with 12 hours of sunlight, stable temperatures and

  • sustainable and clean

water. Area with wide agro-industrial and exports experience. Production area with high level of security and connectivity, close to José María Córdova International Airport.

COMMERCIAL AGREEMENT
slide-8
SLIDE 8

Agro-industrial cluster in Eastern Antioquia less than 20 minutes away from Rionegro’s Free Trade Zone, the JMC International Airport, the municipality of Rionegro and 30 minutes away from Medellín through the Oriente Tunnel.

NORTH

Antioquia Rionegro

Our location

slide-9
SLIDE 9

CULTIVATION

Psychoactive and non-psychoactive cannabis with high productivity and resistance.

FABRICATION

cGMP laboratory for ethanolic extraction with subcritical CO2 for the recovery of terpenes.

FINISHED PRODUCTS

Magistral formulas, phytotherapeutics, cosmetics, dietary supplements, beverages, veterinary products and others.

COMMERCIALIZATION

Local market and exports to Latam, North America, Europe, Asia and Oceania.

SEEDS

High quality registered plant material.

Our business model

slide-10
SLIDE 10

Our milestones and projections

Cannabis-derived manufacturing license License to use cannabis seeds Non-psychoactive cannabis cultivation license Psychoactive cannabis cultivation license Seedling source resolution (106 varieties) Non-psychoactive agronomic evaluation test Approval of psychoactive quotas Psychoactive agronomic evaluation test Greenhouse construction for production Laboratory construction for extraction Beginning of non-psychoactive commercial cultivation

  • Beginning of psychoactive commercial cultivation

JUL 22 JUL/OCT JAN 30 MAR/JUL MAY 29 OCT 11 DEC 16 DEC 17 AUG/DEC SEP/DEC OCT JAN MAY

2020 2021 2019

slide-11
SLIDE 11

Mother plants greenhouse Agronomic evaluation greenhouse Production greenhouse Extraction lab

  • N

ACCESS ROADS PRODUCTION

45 2 . m 1.50m 1 . 5 m

S E M I T Ú N E L

2.947 m2

OFFICES LAB

7,5m 10,10m 9m 15,5m , 6 m 0,5m 3 , 5 m 2m 7,2m 0,8m 0,8m 0,5m 0,5m

PRODUCTION

Our facilities

45 2.00m 1 . 5 m 1.50m

SEMITÚNEL

2 . 9 4 7 m 2 MOTHER PLANTS

AGRONOMIC EVALUATIONS

Total area: 4.7 Ha

El Tablazo, Rionegro, Antioquia

slide-12
SLIDE 12

Superventilated type Anti thrips mesh enclosure Polyethylene for maximum use

  • f solar radiation

Automated drip irrigation system

Total production greenhouse area 2020 10.000 m2 2021 15.000 m2 2022 20.000 m2 2023 30.000 m2 2024 40.000 m2 2025 50.000 m2

Our greenhouses

slide-13
SLIDE 13

Contribution Margin COP$MM

  • 10.000

20.000 30.000 40.000 50.000 60.000 70.000 2021 2022 2023 2024 2025

Contribution Margin USD$K

Projection of results as for 2021-2025

  • 10.000

20.000 30.000 40.000 50.000 60.000 70.000 2021 2023 2024 2025

EBITDA USD$K

2022

  • 5.000

10.000 15.000 20.000 25.000 30.000 35.000 40.000 45.000 2021 2022 2023 2024 2025

  • USD$K
  • 10.000

20.000 30.000 40.000 50.000 60.000 70.000 80.000 90.000 2021 2022 2023 2024 2025

Sales USD$K

slide-14
SLIDE 14 30mL

CBD

50mg/mL S O L U C I Ó N O R A L

Product development

FULL SPECTRUM PHYTOTHERAPEUTICS AND MAGISTRAL FORMULAS

  • O ESTANDARIZADO DE CA
  • rios Medick para Anandamida Gardens S.A.S. Rionegro, Antioquia,

1000mL

FULL SPECTRUM STANDARDIZED CANNABIS EXTRACT

30mL

CBD/THC

  • S O L U C I Ó N O R A L
30mL

THC

50mg/mL S O L U C I Ó N O R A L

CBD

O ESTANDARIZADO DE CA

  • rios Medick para Anandamida Gardens S.A.S. Rionegro, Antioquia,

1000mL

THC

O ESTANDARIZADO DE CA

  • rios Medick para Anandamida Gardens S.A.S. Rionegro, Antioquia,

CBD/THC

  • CBD Oral solution

Dropper bottle 30mL and 10mL

  • 50mg/mL
  • THC Oral solution

Dropper bottle 30mL and 10mL

  • 50mg/mL
  • CBD/THC Oral solution

Dropper bottle 30mL and 10mL

  • 50mg/mL
  • 50mg/mL

CBD 1000mL Bulk

  • THC

1000mL Bulk

  • CBD/THC

1000mL Bulk

  • 1000mL
slide-15
SLIDE 15

Endomedicine is a medical area of focus that deals with prevention, diagnosis and treatment of chronic diseases through modulation

  • f the Human Endocannabinoid System (ECS).

2016 First Symposium on Medicinal Cannabis 300 attending physicians and students Faculty of Medicine Universidad del Cauca 2019 International Seminar on Endomedicine 500 health professionals attendees Parque Telemedellín 2020 Endomedicine Webinar 1000 attendees from 29 countries Webinar for health professionals 2020/2021 Endomedicine Course: medicinal cannabis and complementary therapies aimed at health professionals

Medical education programs

endomedicina

endomedicina

CANNABIS · PSICODÉLICOS · TERAPIAS COMPLEMENTARIAS

W E B I N A R

medicina

endo

II SEMINARIO DE

2019 2020

slide-16
SLIDE 16

Company Ticker *Market Cap

*CDN$ (as of July 24 - 2020)

Pharmacielo Khiron Life Sciences Avicanna Blueberries Medical Medcolcanna PCLO KHRN AVCN BBN MCCN 73.84M 59.21M 36.43M 4.54M 7.68M

Main cannabis companies in Colombia

slide-17
SLIDE 17

www.unicauca.edu.co www.grupocurativa.com www.analdex.org www.fundaciondaya.org www.tni.org www.empirialabs.com www.endomedicina.com

endomedicina

CANNABIS · PSICODÉLICOS · TERAPIAS COMPLEMENTARIAS

Ethan Russo

CERTIFIED NEUROLOGIST Founder of Cannabis Research.org Medical Director at CReDO Science.

Mara Gordon

HEAD OF PROCESS ENGINEER Researcher and Co-founder of Aunt Zelda’s California.

Paola Pineda

SURGEON AND RESEARCHER Medical Director at Grupo Curativa Colombia.

Cristina Sánchez

BIOLOGIST AND RESEARCHER Professor at Universidad Complutense de Madrid.

José Rodríguez Orengo

CHEMIST AND RESEARCHER Professor at the School

  • f Medicine University
  • f Puerto Rico.

Board of advisors

Strategic allies

Garrett Seale

NEUROSCIENTIST AND RESEARCHER Brown university U.S.A.

www.asocolcanna.org www.cannabisclinicians.org www.labmedick.com www.bancoagrario.gov.co www.alpharma.com.co www.asisfarma.com.co

slide-18
SLIDE 18

Diana Paola Valenzuela

LEGAL DIRECTOR

Alexander Gómez

CHIEF OF COMMUNICATIONS

Santiago Bravo

CHIEF OF LOGISTICS

Juliana Hernández

ADMINISTRATIVE LEADER

Zoraida Gutiérrez

OPERATIONAL DIRECTOR

Fáber de Jesús Chica

CHIEF OF CULTIVATION

Adrián López

AGRONOMIST

Lina María Escobar

TECHNICAL DIRECTOR (E)

Jaime Ignacio Gutiérrez

PRESIDENT

Julián Caicedo

MANAGING DIRECTOR

José Joaquín Varela

CHIEF SCIENTIFIC

Freddy Guarín

COMMERCIAL DIRECTOR

Our team

slide-19
SLIDE 19

Carrera 48 No. 16 - 30 Medellín, Colombia. Contact: (4) 5 575811 info@anandamidagardens.com Investor relations: Jaime Ignacio Gutierrez jaime.gutierrez@anandamidagardens.com Visit our website: www.anandamidagardens.com Follow us in: